Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PB2203
- Development stage
- Unknown
- Lead developer
- PB Immune Therapeutics
01
Overview
PB2203 is a human biologic therapeutic candidate under development by PB Immune Therapeutics. It is currently in early-stage clinical development, specifically Phase 1, for the treatment of Graft-versus-Host Disease (GvHD) and other undisclosed indications. PB Immune Therapeutics utilizes advanced immune profiling technologies, including single-cell transcriptomics and spatial transcriptomics, to develop its pipeline of autoimmune and anti-cancer therapeutics. While the specific molecular target and mechanism of action for PB2203 have not been publicly disclosed, it is part of a broader portfolio of human-targeting biologics aimed at modulating immune responses in inflammatory and malignant conditions.
Beyond the preview
Go deeper on PB2203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PB2203.